TUCSON, Ariz., April 6, 2023 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. Scientific Posters presented its proprietary HTG EdgeSeq™ technology at the American Association for Cancer Research (AACR) Annual Meeting April 16-19 in Orlando, Florida.
Cancer research leaders, including the University of Texas MD Anderson Cancer Center, St. John’s Providence Health Center and Merck KGaA, will share research conducted through the HTG EdgeSeq gene expression profiling (GEP) platform. The science presented at AACR highlights the broad spectrum of applications using the ultra-efficient RNA profiling platform HTG and the Company’s capabilities from biomarker discovery and genomic signatures to drug discovery. It stands out among the proposed data analysis from HTG’s powerful tool, the HTG Transcriptome Panel (HTP), which provides a comprehensive and reliable capture of human transcriptome data using a fraction of the sample typically required by other GEP methods.
Posters will be presented at the AACR times listed below, and will be available on our website after the presentation:
- Abstract 2107 – Development of a customized panel with potential clinical application for transcriptome analyzes in selected cancers using FFPE samples Give time: April 17, 2023, 9:00 AM – 12:30 PM
Session: Biomarkers for the Elucidation of Tumor Biology and Metastasis
Location: Orange County Convention Center, Poster Section 38, Poster Board 10
Reporter: Vittorio D’Urso, Clinical Genomics, Clinical Biomarkers & Technologies, Clinical Measurement Sciences, Merck Healthcare KGaA, Darmstadt, Germany
- Abstract 4501 – New EHE PDX model for drug sensitivityGive time: April 18, 2023, 9:00 AM – 12:30 PM
Session: Molecular Targeted Therapies 2
Location: Orange County Convention Center, Poster Section 42, Poster Board 26
Reporter: Sandhya Krishnan, UT MD Anderson Cancer Center, Houston, TX
- Abstract 6375 – Transcriptomic signatures in metanoma of node metastasis relevant to immune oncology therapyGive time: April 19, 2023, 9:00 AM – 12:30 PM
Session: immune checkpoints
Location: Orange County Convention Center, Poster Section 23, Poster Board 19
Reporter: Matias A. Bustos, St. John’s Health Care, Santa Monica, CA
- Abstract 619 – TP53 A gain-of-function mutation modifies the immunosuppressive microenvironment in non-HPV associated oral squamous cell carcinomaGive time: April 16, 2023, 1:30 PM – 5:00 PM
Session: Journal of Immunity to Tumors
Location: Orange County Convention Center, Poster Section 21, Poster Board 20
Reporter: Yewen Shi, Otolaryngology-Head and Neck Surgery, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
“The abstracts highlighting our technology at this year’s AACR conference are a true reflection of the broad utility of our HTG EdgeSeq platform and the great research being done by our customers and collaborators,” said Byron Lawson, SVP and Chief Commercial Officer at HTG. “We are proud to partner with these new centers and new research and biopharma partners who are using our new transcriptomic technology to take their research and science to new heights.”
About HTG:
HTG accelerates precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling for translational research, new therapeutics and clinical diagnostics across a variety of disease areas.
With more than a decade of building innovation and partnerships with leading biopharma and major academic institutions, HTG’s proprietary RNA platform technologies are designed to develop more efficient and effective life science tools and diagnostics and unlock transformative differentiation and disruption. the discovery of drugs. For more information visit www.htgmolecular.com.
Next, look at the statements:
Statements in this release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the capabilities of our technology. Words such as “believe,” “believe,” “anticipate,” “expect,” “potential,” “will” and similar expressions identify forward-looking statements, although not all forward-looking statements necessarily contain these identifications. words These forward-looking statements are based on management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never prove to be material or incorrect. Actual results and the timing of events could differ materially from those forward-looking statements as a result of various risks and uncertainties, including risks associated with drug discovery and development; the danger that our lives may not provide the benefits we hope for; risks associated with our ability to develop and commercialize our products; the risk associated with our ability to license, communicate or otherwise engage in finding or developing any candidates; the risk that our products and services may not be accepted by biopharmaceutical companies or other customers as anticipated or at all; and risks related to our need for additional capital. These and other factors are described in more detail in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our Annual Report on Form XK for the year ended December 31, 2022, as filed. With the SEC on March 30, 2023. All forward-looking statements contained in this press release speak only as of the time they were made, and we undertake no obligation to ensure that such statements reflect existing events or circumstances. after the day on which they were made.
HTG Investor Contact:
Ashley Robinson
LifeSci Advisors
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com
